Reed Jobs, founder of oncology-focused venture capital firm Yosemite and son of Steve Jobs, told Fortune that GLP-1 drugs could be among the most important medicines to reach the market, with possible implications for cancer and cardiovascular disease. He called the GLP-1 revolution one of the biggest biotechnology developments of the past three years, while acknowledging drawbacks such as muscle loss. A JAMA Oncology study of 86,632 adults found GLP-1 users had a 17% lower hazard of developing the 14 cancers studied than nonusers, though the finding shows an association rather than proof that the drugs prevent cancer directly. Jobs said Yosemite's second fund exceeded its $350 million target and was oversubscribed, with AbbVie and Amgen among the investors. A Deloitte report found obesity drugs accounted for 25% of late-stage pipeline sales forecasts for major pharmaceutical companies, up from 1% in 2022.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalshealthcarecancer
Open a keyword to see other news on the same topic.
Related tickers and likely impact
AAPL
• NeutralApple Inc.
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Technology Hardware, Storage & Peripherals |
| Market cap | $5.1T |
| Close on 10/29/2026 | 348.94 |
| Change that session | +1.49% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months, compared with 12.7 months for Imfinzi alone, in patients whose cancer had not progressed after initial Imfinzi and chemotherapy. Nearly 80% of patients on the combination were alive at one year, versus 53% on Imfinzi alone. Imdelltra posted $288 million in second-quarter sales, up 115% year over year, after $627 million in global sales in 2025. Amgen said the results suggest earlier use of the drug could meaningfully alter the course of the disease, though the trial did not compare the combination with other first-line treatments.
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly shares rose over 6% to about $1,370, a record closing high, after third-quarter revenue jumped 39% year over year to $24.4 billion, above the LSEG consensus of $22.6 billion. Adjusted EPS rose 6.6% to $7.48, beating analysts' $6.26 estimate, though a sizable acquisition-related accounting charge held back annual profit growth. Adjusted gross margin reached 84.4%, up from 83.6% a year earlier. Mounjaro revenue climbed 65% to $10.7 billion and Zepbound rose 49% to $5.35 billion, as higher patient volumes more than offset lower realized prices. The price target was raised to $1,500 from $1,300 and the 2 rating was reiterated, with shares up more than 50% since the April 29 close.
- Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine
Jazz Pharmaceuticals reported second-quarter revenue up 16% year over year to $1.2 billion, with Xywav at $471.2 million (up 13.5%) and Epidiolex at $292.1 million (up 16%). Xywav, about 39% of revenue, faces competition from Lumryz and generics for Xyrem, which the author says could weigh on the stock until the company diversifies its portfolio. Oncology revenue rose almost 32% to $362.3 million, led by Zepzelca at $105.8 million (up 42%). Ziihera received a label expansion in August for gastroesophageal adenocarcinoma and is being tested for several other potential indications, while Modeyso was approved in the U.S. last year. The author says the stock is attractive at current levels for investors willing to hold for at least five years, trading at 10.9x forward earnings versus a 19.2x average for healthcare stocks.
- A pharma giant is moving past one patent cliff — but another is already looming
Novartis says remibrutinib, its experimental multiple sclerosis (MS) drug, could generate more than $4 billion in peak annual sales, even though Barclays recently cut its peak sales forecast after late-stage trials showed it reduced relapses by less than analysts expected. The drug belongs to the BTK inhibitor class and aims to regulate immune cell activity rather than eliminate cells, unlike Kesimpta, an anti-CD20 antibody. University of Pennsylvania MS specialist Amit Bar-Or said its safety profile looks promising but it is unlikely to control relapses as effectively as Kesimpta, and its biggest market-expansion opportunity could come from trials in progressive MS, with a readout expected in 2031. Morningstar analyst Jay Lee said the $4 billion-plus forecast is 'within the realm of possibility' but not de-risked. Meanwhile, the market is already looking to the next patent cliff around 2032 for Kisqali and Kesimpta, whose expiries alone represent $18 billion in peak sales.
- Novo Has Big Plans for 2030. Should You Buy the Stock Now?
Novo's shares have dropped more than 60% over the past couple of years as it lost market share in GLP-1 products such as Wegovy, Ozempic, and Rybelsus to Eli Lilly. Its 2030 goals include more than five products each generating several billion dollars in annual sales, revenue growth comparable to industry peers, serving 10 times as many obese patients with oral GLP-1 products, and reaching more than 60 million patients, up from over 45.6 million last year. Candidates such as CagriSema, awaiting approval after beating Wegovy in a head-to-head Phase 3 obesity study, and zenagamtide, in Phase 3 trials, are seen as having blockbuster potential. The author judges Novo fairly well-positioned to reach these goals, helped by licensed candidates such as UBT251 and HRS-1596, while the stock trades at about 12x forward earnings versus an average of 19.2x for healthcare stocks, though clinical setbacks remain a risk.
Related markets
Latest news
- What Eldorado Gold (EGO) Said on Its Q3 Earnings Call
Eldorado Gold said commercial production at its Skouries project is now expected in late 2026, with total project capital rising to about $1.425 billion, though the company says the project remains fully funded. Third-quarter revenue rose 18% year over year to $512 million, supported by an average realized gold price of $4,326 per ounce versus $3,527 a year earlier, and adjusted earnings reached $0.49 per share compared with $0.41. Consolidated free cash flow was negative $191 million as the company continued investing in Skouries and McIlvenna Bay. Eldorado cut 2026 gold production guidance for its established mines to 410,000–430,000 ounces, excluding the two new projects, which are expected to reach nameplate capacity around mid-2027. The company has offtake contracts covering most expected Skouries output over the next two and a half years.
- Could Apple's First Touchscreen MacBook Pro, First Foldable iPhone Duo Phone, and HomeView Pole Vault Apple Beyond Nvidia to Become the First Company in the $10 Trillion Club?
Nvidia became the first company to reach a $5 trillion market capitalization last year on the back of the AI boom, but its shares have recently been pressured by concerns over AI financing, while Apple has hit record highs and at one point in a recent session passed Nvidia as the most valuable company. Apple's rally is driven by consumer devices, including the foldable iPhone Duo, the HomeView smart home display and a touchscreen MacBook Pro. Apple's fiscal third-quarter revenue rose 16%, and between Oct. 6 and Oct. 23 its market value rose about 4% while Nvidia's fell nearly 12%. Reaching $10 trillion would require Apple's value to climb nearly 100% from about $5.1 trillion today, and the stock trades at about 37 times forward earnings, with analysts expecting roughly 8% earnings growth next year. The author views $10 trillion as a long-term possibility rather than a near-term outcome, and says Nvidia may be just as likely to reach it first.
- Oracle Just Capped How Much New Money It Will Raise. I'd Consider Buying a Small Stake in the Stock.
At its investor day, Oracle repeated targets of at least $225 billion in fiscal 2030 revenue and $21 per share in non-GAAP earnings. Oracle will cap new stock and debt at $20 billion over fiscal 2027–2030, split $10 billion each, on top of $20 billion of stock already sold, versus $48 billion raised in fiscal 2026 when free cash flow was negative $23.7 billion. Management expects free cash flow to turn positive in the second half of fiscal 2028 and reach $30 billion or more in fiscal 2029. The author notes shares near $145 are down about 56% from their record close, and that at about 18 times the $8.10 adjusted earnings expected this fiscal year, the price looks reasonable. The author would consider a small stake and add more once capital spending starts to fall.
- 'Whale' Investors Rush to Pull Crypto Off Exchanges After Binance Hack
Institutional investors are rapidly withdrawing assets from centralized exchanges after the Binance hack to reduce security risks, according to CoinDesk, though the size of these outflows and their destinations have not been determined. Binance estimates total stolen assets at about 6.3 billion USD, of which around 3 billion USD has been frozen, including 2.3 billion USD in the stablecoins USDT and USDC. The main cause may involve a compromised laptop belonging to an engineer; Binance has temporarily suspended withdrawals, and co-CEO Yi He said the platform will cover all losses from the attack. Bitcoin dipped to a low of about 76,460 USD, and total liquidations reached 1.53 billion USD over 24 hours, nearly 84% of them long positions.
- The Smartest AI Stock to Buy on Anthropic's IPO Filing Isn't Anthropic
Anthropic has filed an S-1 with the SEC, signaling a future IPO, and lists Nvidia among its major industry partners. The author notes Anthropic uses multiple chips, and Nvidia's GPUs are heavily used in cloud environments where customers run Claude-based products. Nvidia expects global AI data center capital expenditures to reach $3 trillion to $4 trillion annually by 2030 and has guided for 70% revenue growth in 2027. Yet the stock trades at about 23 times this year's earnings estimates, 13.6 times next year's, and 27 times trailing earnings, which the author says does not reflect growth beyond 2026. The author argues Nvidia remains a strong AI investment, and other companies' 2027 spending plans could confirm that view.
- Trump Reveals Why the US Sent a Letter to Iran's Leaders
President Donald Trump denied directing Vice President JD Vance to send a letter to Iran to explore resuming peace talks, saying Vance proposed it to offer medical supplies. The Wall Street Journal, citing a source, reported the letter was sent on Trump's instructions and aimed to persuade Trump against a sudden, large-scale strike on Iran. Iran's Tasnim news agency said Tehran received the letter but has not responded, and repeated conditions including lifting the US naval blockade of Iranian ports and ending sanctions on its oil exports. A senior Iranian official said proposals from Qatar were unacceptable, while US military options remain under consideration after Admiral Brad Cooper briefed Trump at the White House.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.